| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07555470 Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma |
Recruitment opened |
| 2026-06-04 | NCT05091424 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a… |
date change Primary completion pushed: 2028-05-31 -> 2031-02-10 |
| 2026-06-04 | NCT05091424 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a… |
date change Completion pushed: 2030-02-28 -> 2032-02-10 |
| 2026-06-04 | NCT05207670 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab… |
date change Primary completion moved earlier: 2028-07-31 -> 2027-07-31 |
| 2026-06-04 | NCT05207670 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab… |
date change Completion moved earlier: 2028-07-31 -> 2027-07-31 |
| 2026-06-02 | NCT05412290 Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT05412290 Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma |
Enrollment reduced: 15 -> 9 participants |
| 2026-05-27 | NCT04889716 CAR-T Followed by Bispecific Antibodies |
Primary endpoint(s) modified |
| 2026-05-27 | NCT04889716 CAR-T Followed by Bispecific Antibodies |
Enrollment reduced: 42 -> 23 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07638722 Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating… | Phase 2 | Not Yet Recruiting |
| 2026-05-20 | NCT07598396 A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With… | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06284122 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy… | Follicular Lymphoma | Recruiting |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden… | Classic Follicular Lymphoma | Recruiting |
| NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With… | Relapsed or Refractory Follicular Lymphoma | Active, Not Recruiting |
| NCT05171647 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab… | Non-Hodgkin Lymphoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT04792502 | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and… | Follicular Lymphoma | Recruiting |
| NCT05260957 | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed… | Refractory Non-Hodgkin Lymphoma | Recruiting |
| NCT06563505 | A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory… | Lymphoma | Recruiting |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory… | Diffuse Large B-Cell Lymphoma | Recruiting |
| NCT06442475 | Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma | Ann Arbor Stage II Follicular Lymphoma | Recruiting |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory… | Recurrent Diffuse Large B-Cell Lymphoma | Recruiting |
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in… | Nodular Lymphocyte Predominant B-Cell Lymphoma | Recruiting |
| NCT05389293 | A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | Follicular Lymphoma | Recruiting |
| NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients… | Hodgkin Lymphoma | Recruiting |
| NCT04889716 | CAR-T Followed by Bispecific Antibodies | Large B-cell Lymphoma | Recruiting |
| NCT07598396 | A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With… | Lupus | Recruiting |
| NCT06948786 | Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A… | Grade 1 Follicular Lymphoma | Recruiting |
| NCT07555470 | Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | Follicular Lymphoma | Recruiting |
| NCT05994235 | Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | Follicular Lymphoma | Active, Not Recruiting |
| NCT07548450 | Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory… | Waldenstrom Macroglobulinemia | Not Yet Recruiting |
| NCT06594939 | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly… | Diffuse Large B Cell Lymphoma (DLBCL) | Not Yet Recruiting |
| NCT07566364 | Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With… | Lymphocytic Leukemia | Not Yet Recruiting |
| NCT05207670 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab… | Non-Hodgkin Lymphoma | Active, Not Recruiting |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating… | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in… | Relapsed/Refractory Non-Hodgkin Lymphoma | Recruiting |
| NCT06249191 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc… | Diffuse Large B-Cell Lymphoma | Recruiting |